Tendon injuries are a common and rising occurrence, associated with significant impairment to quality of life and financial burden to the healthcare system. Clinically, they represent an unresolved problem, due to poor natural tendon healing and the inability of current treatment strategies to restore the tendon to its native state. Tissue engineering offers a promising alternative, with the incorporation of scaffolds, cells and growth factors to support the complete regeneration of the tendon. The materials used in tendon engineering to date have provided significant advances in structural integrity and biological compatibility and in many cases the results obtained are superior to those observed in natural healing. However, grafts fail to reproduce the qualities of the pre-injured tendon and each has weaknesses subject to its constituent parts. Furthermore, many materials and cell types are being investigated concurrently, with seemingly little association or comparison between research results. In this review the properties of the most-investigated and effective components have been appraised in light of the surrounding literature, with research from early in-vitro experiments to clinical trials being discussed. Extensive comparisons have been made between scaffolds, cell types and growth factors used, listing strengths and weaknesses to provide a stable platform for future research. Promising future endeavours are also described in the field of nanocomposite material science, stem cell sources and growth factors, which may bypass weaknesses found in individual elements. The future of tendon engineering looks bright, with growing understanding in material technology, cell and growth factor application and encouraging recent advances bringing us ever closer to regenerating the native tendon.
INTRODUCTION
Tendon is a compositionally intricate, fibrous connective tissue which connects muscle to bone. Its function is predominantly mechanical, transmitting tensile forces from the muscle to the bone and hence translating muscle contractions to joint movements. Tendon also increases the efficiency of movement by passively storing and subsequently releasing energy during a joint-loading cycle (Fig. 1) . As a result of its viscoelastic nature it functions as a buffer, dissipating stress concentrations which could potentially result from a direct muscle to bone connection and hence contributes in protecting muscle and bone from damage. 1 Tendon and ligament injuries are common musculoskeletal injuries, with approximately 800,000 patients requiring surgical intervention in the USA each year. 2 They cost the USA an estimated $30 billion per annum. 3 The Achilles tendon, patellar tendon and shoulder rotator cuff are the most frequently affected. 4 5 The incidence of tendon injuries has increased over the past decades owing to the ageing population 6 and an increased emphasis on physical activity. 7 Tendon injuries may range from chronic tendinopathies, considered to be overuse injuries caused by repetitive mechanical loading; to acute ruptures, caused primarily by trauma or inflammatory processes. 1 8 9 Tendon pathology can be highly debilitating, resulting in pain, loss of muscle function, joint instability, abnormal joint motions and could lead to secondary osteoarthritis in the long term. 4 10 All of the aforementioned not only adversely affect a patient's quality of life but also add financial pressure to the healthcare system.
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intrinsic mechanisms of tendon repair. 11 Surgical repair is the current gold standard therapy and utilises autografts, allografts, xenografts, tendon prostheses and suture techniques 12 ( Fig. 2 ). However, tendon injuries clinically represent a still unresolved problem, since strategies followed for repair have failed to provide a tendon which is adequate functionally and mechanically (Table I ). The main reason behind this is the limited intrinsic capacity of tendons to repair and regenerate, owing to their low metabolic rate, hypocellularity and low vascularity 2 (Fig. 3) . Natural tendon healing is often characterised by fibrous scarring and a distorted extra-cellular matrix (ECM), with misaligned collagen fibrils and adhesion formation leading to a loss of function (Fig. 4) . As a result, the healed tendon has inferior biochemical and mechanical properties and is hence susceptible to re-injury. The therapeutic efficacy of surgical treatment modalities is further limited by donor site morbidity, pain, graft failure and high rates of tendon tearing recurrence. Figure 2 . Tendon repair strategies. Keys: DS, donor site; GF, growth factors; PTa/x, patellar tendon allograft/xenograft; PTp, patellar tendon graft from patient; RQT, repaired quadriceps tendon; RT, regenerated tendon; TD, tendon defect; TETG, tissue engineered tendon graft.
The limited healing potential of the tendon and the inadequacy of current surgical treatment options have hastened the drive to develop alternative treatment modalities to promote tendon tissue regeneration. The ideal objective would be to restore the tendon to its pre-injured state. This is the goal of tissue engineering (TE) [15] [16] [17] [18] [19] of tendons, a growing field which aims to combine scaffolds, cells and growth factors to form constructs that will aid regeneration of the native tendon. This review will focus on the application of tissue engineering strategies for tendon regeneration, including the selection and design of scaffold materials, cell sources and growth factors that may overcome limitations of current methods used for tendon reconstruction.
TISSUE ENGINEERING OF TENDONS Scaffold Materials
The primary role of scaffolds in tendon tissue engineering (TTE) is to provide structural support to promote tissue healing. They can 'off-load' the initial repair of the injured tendon and encourage regeneration through tissue remodelling. To achieve this, specific scaffold requirements have been identified that improve viability and functionality of the graft (Table II and Fig. 5) .
A number of natural and synthetic materials have been studied as potential scaffold materials for TTE (Tables III-V and Fig. 6 ). These can be broadly divided into natural, synthetic and decellularised scaffolds. 7 days) ; b, Proliferation (7-21 days); c, Remodelling (21 days-2 years). AP, activated platelets; BV, blood vessel; C I, collagen type I; C III, collagen type III; DBV, damaged blood vessel; DT, damaged tendon; EC, endothelial cells; F, fibroblasts; GF, growth factors; L, lymphocytes; M, monocytes; N, neutrophils; TC, tenocytes. 
Natural Scaffolds
The most studied natural material to date is collagen I. Collagen I is the main component of native tendon tissue, forming over 90% of extra-cellular protein in tendon and ligament 58 (Figs. 3, 7) . TTE scaffolds use collagen-derived materials: hydrophilic polymers that promote cell attachment, proliferation and migration. Used in animal models, collagen scaffolds resulted in aligned tendon fibroblasts and collagen I by 12 weeks, with an increase in tendon thickness. 59 By 26 weeks, there was no evidence of the collagen scaffold, but graft thickness had increased, showing that the scaffold had degraded with adequate support of the tissue. This was maintained at 52 weeks, with no immune response observed. Collagen, therefore, displays good biocompatibility and integration into host tissue. However, as suggested in this study, collagen does not have robust mechanical properties and tends to lose stability through degeneration over time. This is particularly important when considering the various dimensions of defects in other tendons in the body (Table VI) . Earlier research found the mechanical strength of collagen scaffolds to be insufficient to meet in-vivo requirements. 22 However, various processing methods have improved this. Manufacturing the collagen scaffold into a sponge arrangement has been shown to increase the maximum force sustained before rupture and produced a tangent stiffness matching that of normal tendon up to peak in vivo forces. 3 Incorporation of a basal-strengthening membrane has further improved mechanical strength and maintained cell adherence and proliferation qualities. 68 Multi-lamellar collagen scaffolds have also been utilised, which display tensile strength seven-fold greater than mono-lamellar collagen membranes. 69 Scaffolds must also meet the needs of the specific tissue of study. Tendon fibres are arranged in parallel in the native tendon, so it is likely that orientation of scaffold fibres will be important, to accommodate tendon alignment once seeded. 69 Collagen fibres similarly orientated in parallel showed greater cell viability and proliferation once seeded with fibroblasts and tenocytes, compared with misaligned collagen scaffolds. Furthermore, aligned fibres have been found to increase tensile strength and ECM secretion by fibroblasts, 70 laying a superior foundation for in-vivo regeneration of tissue. The importance of scaffold alignment can be explained by 'contact guidance theory,' which proposes that a cell has the greatest probability of migrating in directions associated with structural, chemical and mechanical properties of the substratum. 71 Collagen has therefore proved to be a valuable material in TTE. It is largely biocompatible, biodegradable and demonstrates good biofunctionality with cellular material. Issues with this material are that it currently displays insufficient mechanical properties for in-vivo use, though this is under constant improvement. Collagen also displays limited processability, which restricts the potential pliability of the collagen scaffold ultrastructure. Further research is required to assess collagen scaffold use in human patients.
Silk is another natural scaffold material which stimulates cell attachment, proliferation and ECM production. Its use in tissue engineering was first demonstrated through regeneration of the anterior cruciate ligament, where it displayed suitable biofunctionality with bone marrowderived mesenchymal stem cell (BMSC) attachment and differentiation. 72 It has been proposed that by altering the organisation of the silk fibres; for example by weaving them in a rope-like manner, it is possible to produce scaffold material with mechanical properties similar to normal tendon tissue. Knitted silk scaffolds combined with collagen have therefore been used, which greatly improve mechanical strength. 44 73 Bombyx silk is another form of silk, found to display good cell adhesion, proliferation and non-cytotoxicity in TTE. 74 Recent work found that Bombyx silk scaffolds promoted human tenocyte adherence and histologically resembled tendon in culture. 75 Breaking point strain of the graft was at the level of natural human hamstring tendon. Furthermore, ultimate tensile strength and Young's modulus of the structures was significantly greater than that of natural human hamstring tendon. These results demonstrate that silk can provide a mechanically stable scaffold for TTE, though more research is required to investigate immune response in human studies.
Chitosan is a natural polysaccharide material composed of glucosamine residues, which are also present in the chemical structure of tendon glucosaminoglycans. It is a biodegradable material that displays good biofunctionality because of its hydrophilic nature and glucosamine moieties. It is therefore able to reinforce the mechanical integrity of scaffolds, while also displaying excellent cell adhesive properties due to the presence of amine groups. 76 Chitosan scaffolds have demonstrated adequate biodegradability and adherence of tendon fibroblasts, with subsequent increase in tangent modulus. 77 Recent research has also shown that composite chitosan/polyethylene oxide (CS/PEO) nanofibres display superior stiffness and resilience to erosion in an aqueous medium, when compared to other synthetic polymers: polyvinyl alcohol (PVA), PEO and the composite material PVA/hyaluronic acid (PVA/HA). 78 This study concluded therefore, that CS/PEO possesses the most appropriate attributes for tendon and bone tissue engineering. Chitosan is also an easily processable material, making this material well-suited for TTE. Further work is still required, however, to assess the biofunctionality of this material in animal models. In-vitro and in-vivo: Autologous cells seeded on scaffolds and cultured for 7 days before implantation to repair tendon defects of pigs.
Both dermal fibroblast and tenocyte engineered tendons shared similar macroscopic and histological appearance as well as mechanical strength that was about 75% of normal tendon strength. Notes: ASCs, adipose stem cells; CG, collagen-glycosaminglycan; ECM, extracellular matrix; hMSCs, human mesenchymal stem cells; N/A, not applicable; NP, nanoparticle; MSCs, mesenchymal stem cells; PCL, poly( -caprolactone); PDGF, platelet-derived growth factor; PDS, polydioxanone; PGA, poly(glycolic acid); PLGA, poly(lactic-co-glycolic acid); PLGA-m-PEG, poly(lactic-co-glycolic)-m-poly(ethylene-glycol); PLLA, poly(L-lactic) acid; P(LLA-CL), poly(l-lactide-co--caprolactone); PU, polyurethane; SEM, scanning electron microscopy; THF, tetrohydrofuran; TIPS, thermally induced phase separation.
Composite natural scaffolds have been explored, which have the potential to bypass inadequacies found in individual materials. Chitosan and HA hybrid polymer scaffolds have demonstrated biocompatibility with fibroblasts, with an increase in function up to 12 weeks. Chitosan is a cationic polysaccharide, while HA displays anionic qualities, so the increase in mechanical strength is attributed to the tight-interaction polyion complex between the polymers. Functionally, the combination of 0.1% HA to the chitosan scaffold also significantly improved cell proliferation at 28 days. 77 Collagen-glycosaminoglycan composite scaffolds were created by freeze drying and vacuum sublimation. 30 These core-shell composite scaffolds showed improved mechanical integrity, providing a porous structure to promote vascularisation and contact guidance cues for the regenerating tendons. The tensile moduli of 155 m scaffolds was 36 fold higher than aligned collagen glycosaminoglycan scaffolds. No difference was found in metabolic activity and proliferation of tendon cells, however, suggesting that improvement was mainly mechanical.
An amalgamation of collagen and HA has also been formed using a self-assembly strategy, that displays nanofibrous architecture in a 130 m membrane. 79 This material promotes MSC proliferation and remains stable in fluid and physiological temperature. Upon cross-linking the mechanical properties can also be increased seven-fold, demonstrating that this material provides high processability. In-vitro analysis has also revealed enhanced resistance to enzymatic and thermal degradation, while also promoting fibroblast attachment and proliferation. 80 Although still a novel strategy in TTE, combination natural scaffolds such as these have demonstrated significant advantages to individual materials and may prove substantial in the future.
Decellularised Scaffolds
Decellularisation of the native tendon is another method used to produce natural tendon scaffolds. Tissues are subjected to a rigorous process of cleaning, removal of lipids, destruction of DNA, cross-linking and sterilization to remove cellular material that could provoke a host immune reaction. 81 The remaining extra-cellular matrix has a 3D ultrastructure, composed mostly of collagen. Tissue types that have been used include small intestine submucosa (SIS), pericardium and dermis, usually obtained from humans or commonly reared animals, namely: porcine, bovine and equine sources. SIS has been used extensively in TTE. In a rat-model of tendon injury, SIS was found to promote neovascularization and provided mechanical strength greater than a natural healing control. 82 Study in canines found histological results with SIS to be similar to the native tendon. 83 However, ultimate load failure was no greater than sham surgical repair and only half the value found in the native tendon. Research with SIS has progressed to commercially available scaffolds such as Restore ® and CuffPatch ® (Table VII) , which are used as adjuncts to surgical repair.
Restore ® was the first commercially available biologic device in TTE. Clinical studies using Restore ® have provided largely unfavourable results. In rotator cuff repair, a large proportion of human patients developed inflammatory responses, which caused breakdown of the repair and required re-operation. 89 90 On functional analysis, it was found that patients had restricted arm movements postoperatively, pain took longer to resolve and patients had less participation in sports compared to controls that had undergone conventional rotator cuff repair. 90 This has been supported by other studies, which found no benefit in using the Restore scaffold in the repair of rotator cuff tears. 91 92 Analysis in rabbits and mice revealed that the scaffold was not completely acellular and contained porcine cells, which produced an inflammatory and fibrotic reaction in the animals. 86 These results suggest that the Restore ® graft may be unsuitable for clinical use in TTE.
Acellular human dermis is another commonly-used material for tendon regeneration. In a canine-model of infraspinatus injury, histological analysis at three months shows similar organisation to the native tendon. 93 Mechanical strength, however, was no greater than the control surgically repaired tendon. Graft Jacket is a commercially available scaffold formed from decellularised human dermis. Used in clinical trials for rotator cuff repair, it has shown good integration into surrounding tissue on MRI, with improved functional performance in measures of pain and range of movement. 94 95 Histological analysis three months following rotator cuff repair with GraftJacket ® has also shown good integration and vascularisation, with no signs of inflammation. 96 Furthermore, in Achilles tendon repair, GraftJacket ® has demonstrated improved functional outcome and appropriate tissue integration. [97] [98] [99] GraftJacket ® has therefore provided good clinical use as a repair adjunct; however, the cases described have been carefully selected, hence further research is required before wide-spread use can be indicated. Additionally, blinded comparison with other therapeutic strategies should be undertaken to fully assess the benefit of acellular dermal grafts in the clinical context.
An intrinsic issue with decellularised scaffolds is that they rely on the presence of donor tissue. While donor tissue has been obtained from xenogenic sources, the increased difficulty in growing this tissue and the process of decellularisation, add to the time and expense of generating these scaffolds. They are therefore, not the ideal scaffold material for tendon tissue engineering.
Synthetic Scaffolds
Synthetic scaffolds are chemically formed polymers, artificially designed to suit the requirements of the healing tendon. The most studied synthetic scaffold materials are polyglycolic acid (PGA) and poly-L-lactic acid (PLLA) or their co-polymers (PLGA). These scaffolds are biodegradable, with degradation products naturally present in the body. PGA scaffold use has been demonstrated in large animal models, displaying good biocompatibility, biodegradability and cell incorporation with tenocytes and human dermal cells. 33 Even when un-seeded, new cell growth was observed, suggesting that this scaffold displays good integration and promotes cell migration. Tensile strength of the regenerated tendon was 75% of the native tendon, which is superior to results achieved with many other regenerative methods and the current gold-standard of surgical treatment. However, PGA has been found to be detrimental to matrix formation, which is believed to be due to local acidic effects caused by rapid breakdown byproducts. 100 This swift degradation may make PGA unsuitable for TTE, which requires long-term cell support.
Use of PLLA has yielded mixed results. Early work in a sheep model of tendon injury demonstrated significantly increased ultimate load strength in the PLLA scaffold compared with untreated controls. 101 Further work largely supports these results, though results were still significantly lower than that of the normal, un-injured tendon.
In addition, a fibrotic ingrowth was observed at the augmented scaffold-host cell interface. 102 This inflammatory reaction has been confirmed in other studies, which were unable to demonstrate a significant difference between the scaffold and the natural repair control. 103 Worryingly, 57% of the scaffold group also displayed humeral fractures, which did not occur in the control group. More recent in-vitro work suggests that PLLA increases ultimate load and yield, though has no effect on initial stiffness of the scaffold. 104 As this was an in-vitro cadaveric study, however, no observations could be made on immune reaction. These results, suggest that in the light of the success of other materials in TTE, PLLA scaffolds are a weak candidate for future clinical application. PLGA scaffolds have exhibited superior cell proliferation and adhesion compared with PLLA and polycaprolactone (PCL) scaffolds. Due to the increased internal connective space, knitted PLGA scaffolds seeded with BMSCs were used for repair of Achilles tendon of rabbits with a 10 mm defect. 47 Two weeks postoperatively, a large number of proliferating cells and regeneration of matrix was observed, with oriented collagen fibres observed in four weeks. PLGA therefore displays good Figure 6 . Complex scaffold designs in tendon tissue engineering. Scaffold designs suggested by: (a) [30] ; (b) [57] ; (c) [47] ; (d) [34] ; (e) [106] ; (f) [20] ; (g) [105] . These figure has been redrawn. Notes: BGM, bioactive glass microspheres; bMSCs, bone marrow mesenchymal stem cells; CHS, chitosan-hyaluronan scaffold; CPM, copolymer microspheres; HDCG, high density collagen-glycosaminglycan; KMS, knitted mesh sheets; LDCG, low density collagen-glycosaminglycan; MPCs, mouse preosteoblast cells; PCL, polycaprolactone; PG, polyglactin; PLGA, poly(lactic-coglycolic acid); PLLA, poly(L-lactic acid); SBF, simulated body fluid; TB, tenoblasts. biocompatibility. A major issue, however, is that PLGA also degrades too rapidly. Early research found that the scaffold loses 99% of its mechanical strength within four weeks. 105 Given the slow rate of tendon growth, it is advisable for scaffolds to be able to retain at least 50% of their mechanical strength at 3 months. Therefore, PLGA fibres alone would be unsuitable for use in TTE. Silk fibroin fibres incorporated into a PLGA scaffold were found to increase mechanical strength, while maintaining biocompatibility of the scaffold with BMSCs. 31 A potentially major issue, however, is that the scaffold was found to significantly degrade in phosphate buffered saline (PBS), which could affect its in-vivo integrity. Fabrication of electrospun nanofibre scaffolds of PLGA with aligned and unaligned fibres have also been investigated for functional rotator cuff engineering. 106 These degradable, porous scaffolds resemble the ultrastructure of tendon and results showed that aligned nanofibrous PLGA scaffolds possess significantly higher mechanical properties than unaligned scaffolds.
A comparison of seven different types of polyhydroxyalkoanates has been carried out using mouse connective tissue cell-seeded constructs. 107 Results indicated that all scaffolds exhibit good cell proliferation. Poly(3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBHHx), however, had the highest proliferation, viability and matrix production. PHBHHx scaffolds have also demonstrated good biocompatibility and mechanical properties in a rat model (Achilles tendon). 39 In addition, this scaffold encouraged active migration, proliferation and facilitated quick restoration of functionality (measured by Achilles Functional Index) over 20 days. A few studies have compared the functional characteristics of natural and synthetic scaffolds. Recent investigation compared a natural collagen sponge scaffold (Col-Spo) with a synthetic polyglycolic acid/PDS scaffold (PP-sca), 68 seeded with tendon-derived cells (TDCs). Both scaffolds permitted cell adherence, though the PP-sca displayed a more efficient adherence of cells, with lower initial cell attrition. Proliferation rates were found to be equal, though they were significantly lower than in un-seeded control cells. In terms of mechanical strength, the Col-Spo exhibited a seven-fold higher tensile strength, which contrasts with other studies which comment on the poor strength of collagen scaffolds. Therefore, collagen scaffolds may provide a more suitable platform for TTE.
POSS-PCU scaffolds promoted cell adhesion and proliferation and demonstrated high biocompatibility and non-toxicity for many tissue engineering applications including tracheal, vascular, dermal tissue engineering and nerve regeneration. POSS-PCU possesses both the mechanical and viscoelastic properties required for TTE and therefore shows a lot of potential for future work. Currently POSS-PCU is being investigated by our research group for tendon engineering and provides a promising alternative for the future of TTE.
A technique known as electrospinning (theory and applications see review 108 has already been used extensively in tissue engineering. 109 It allows improved augmentation of the structure of materials to match the requirements of the tissue. Different materials can also be combined in this process, to bypass limitations in individual components. Synthetic PCL combined with collagen through electrospinning was found to increase tensile strength in skin scaffolds, with even 10% PCL significantly improving the tensile strength of collagen. 110 A major issue with these scaffolds, however, is that the production of nanofibre layers produces a packed structure too tight to allow the infiltration and growth of cells. 111 Porosity is important in nutrition, transport and metabolite release, which would explain the limited growth capacity in tightly packed structures. 112 113 To overcome this issue, a grounded spherical dish and needle-like probes were used after electrospinning, to create a focused low density uncompressed nanofibre (FLUF) mesh scaffold which, rather fittingly, resembles a cotton-ball in shape. 114 This was found to produce a 3D nano-fibrous structure with larger pores, hence improving cell infiltration and proliferation. For tendon regeneration, however, where scaffold orientation plays an important role, this cotton-ball shape may not be appropriate. Recent work instead combined the synthetic polymer poly(l-lactide-co-e-caprolactone) [P(LLACL)] with collagen using electrospinning in a dynamic liquid supporting system. 23 The resulting nanoyarn possessed sufficient mechanical characteristics and a porous structure that enabled it to promote proliferation of tenocytes deep within the scaffold. Expression of tendon-related ECM genes was also upregulated in the seeded tenocytes.
Fibre diameter has been proposed as an important element in the host-immune response to biological scaffolds. Electrospun materials may, therefore, reduce the likelihood of immune reaction as the nanofibres have smaller fibre diameter than traditionally produced films and microfibrous scaffolds. 115 Electrospinning is a valuable technique in scaffold manipulation and future in-vivo work is likely to confirm the improvements it contributes to scaffold performance.
Cell Seeding
Early research in tissue engineering has shown that cells implanted onto TE scaffolds improve the outcome of the graft. This 'seeding' of cells is particularly important in TTE because native tenocytes re-grow very slowly following damage. Embedding cells into the implanted scaffold therefore increases support and occupance of the wound area, while also providing a seamless link between scaffold and host tissue.
Research strategies have incorporated either adult somatic cells, namely tendon fibroblasts and dermal fibroblasts or stem cells, with each providing advantages and disadvantages (Tables III-V and Figs. 8, 9 ).
Adult Somatic Cells
The majority of research has focussed on tendon fibroblasts, or tenocytes. Early research in a hen-model of tendon injury found a marked improvement in graft mechanical strength after seeding tenocytes on PGA scaffolds. 48 After 14 weeks, scaffold breaking strength improved almost ten-fold following addition of the tenocytes; producing a mechanical strength 83% that of the native tendon. Moreover, tissue histology at 14 weeks was indistinguishable from native tendon tissue. Tenocytes can attach and proliferate on various scaffold types, take part in ECM production by synthesising collagen I and III and can improve mechanical strength of the graft. However, contrasting studies have found no significant increase in mechanical strength using tenocytes. 77 The main disadvantages of using tendon fibroblasts are their limited life span and the difficulty of extraction, as the procedure usually requires surgery. In addition, the hypocellular structure of tendons makes it difficult to obtain a large number of cells, 116 which can show limited expansion in culture with growth factors. 24 These limitations make tenocytes a difficult selection for TTE.
Dermal fibroblasts are an alternative cell type used in TTE. Unlike tendon fibroblasts, they are easily accessible and abundantly located around the body. Structural difference between skin and tendon tissues has raised question about the suitability of these cells for TTE. However, research has shown that dermal fibroblasts grown on a PGA matrix produce very similar features to tenocytes. 33 117 This research has also translated to human clinical trials. A randomised control trial compared the introduction of dermal fibroblasts with autologous plasma alone in patients with patellar tendinopathy. 118 It was found that dermal fibroblasts significantly improved pain, severity and functional disability, as assessed by the Victorian Institute of Sport Assessment (VISA) score. With their practical advantages, dermal fibroblasts may, therefore, present a more pragmatic alternative to the tendon fibroblast in TTE. A drawback, however, is that these cells are also terminally differentiated. As a result, they lack unlimited self-renewal and their limited life-span could impair the long-term functional output of the graft.
Human Embryonic Stem Cells
Stem cells may have self-renewal characteristics and have therefore been investigated as an alternative cell-seeding source in TTE. Human embryonic stem cells (hESCs) can be differentiated in-vitro and transferred into the target tissue. The ability of these cells to differentiate into mesenchymal lineages has been extensively investigated. [119] [120] [121] [122] [123] Recent work has provided a more efficient means of deriving connective tissue progenitors (CTPs) from hESCs, for use in TTE. 124 CTPs are partially differentiated cells, indicated by the expression of multiple lineage-specific genes and proteins. In this study, CTPs were grown into tendons, which improved in-vivo function, in comparison to an untreated control. This cell-type confers many advantages in that it can self-renew at a rapid rate, meaning a small extract can produce a large volume of cells to fill tissue defects. hESCs are also pluripotent, raising the prospect that all musculoskeletal and connective tissue could be derived from one source, providing a more holistic regeneration of damaged tissue. An issue with primary hESCs, however, is that given this maintained pluripotency, there is a significant tumorigenic potential to produce teratomas.
Although not observed at 6 months in this study, this phenomenon has been described elsewhere and could pose a risk to future clinical use. Inappropriate differentiation of tissue can also take place, with bone formation being observed in in-situ patella tendon repair. 125 Furthermore, ethical issues remain concerning the use of embryonic stem cells and may decrease public interest in the use of this cell type.
Amniotic Epithelial Cells
Amniotic epithelial cells (AECs) have been used extensively for tissue engineering. They are derived from the amniotic epithelial layer of the growing foetus and could be a reliable source of pluripotent stem cells. AECs show advantages over primary hESCs, as they have a low tumorigenic potential. 126 They also display antiinflammatory 127 and anti-microbial properties, 128 with a low immunogenicity. 129 After transplantation into tendon, AECs were found to differentiate into tenocyte-like cells, with morphology similar to that of the native tendon. 130 Cellular integration and function was pronounced, with increased expression of VEGF, suggesting that the AECs increase angiogenesis and vascular remodelling. The AEC group showed increased initial inflammation, but over time this decreased to the level of the native tendon; whereas, in the control healing tendon, inflammation continued to increase. Overall, mechanical properties of the tendon improved significantly with addition of AECs, making them a promising candidate for TTE.
Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs) are another stem cell source used for tissue engineering of tendons. These cells can differentiate into any mesenchymal cell type, including bone, muscle, cartilage, fat and tendon. They can also be derived from several sources in the body, though research is centred on MSCs obtained from bone marrow [131] [132] [133] and adipose tissue. 134 135 MSCs from these sources have been shown to display similar differentiation potential and expression profiles. 136 Use of MSCs in TTE has yielded largely successful results. Bone marrow-derived MSCs (BMSCs) seeded on collagen gels displayed significantly improved mechanical strength 32 137 and a linear stiffness 75% that of the native patellar tendon, against only 30% in acellular scaffolds. 32 Histologically, the application of MSCs produces tissue organisation much more akin to native tissue than un-treated controls. 32 This study also failed to find any evidence of the inappropriate osteogenesis which has been reported elsewhere. 125 However, other reports have found no improvement with the use of BMSCs. One study found that at four weeks, tendons treated with BMSCs showed significant increase from two weeks, but no significant difference to untreated controls in mechanical strength and histological appearance. 138 Another study suggested an improvement in mechanical strength only in early stage healing, with no further improvement after three weeks. 139 Important limitations with this study, however, are that there was no further analysis of the grafts after four weeks, whilst most studies continue for longer than eight weeks. Furthermore, in this study BMSCs were introduced only with fibrin glue; no significant scaffold or growth factors were co-administered. It is plausible; therefore, that differentiation of the BMSCs may not have taken place at a level to provide an effective increase in function of the graft.
MSCs derived from adipose tissue (ASCs) have also been shown to differentiate into tendon-specific lineages. Work in TTE has shown that ASCs significantly improve mechanical strength and secretion of tendon-related ECM proteins. 140 As ASCs are much easier to extract than BMSCs, it follows that they may be more suitable candidates for cell seeding in tissue regeneration. However, less research has been carried out on this cell type, so further investigation is required to assess the beneficial and adverse effects of their use.
MSCs display two characteristics that make them wellsuited to tissue engineering. Firstly, they produce a number of paracrine factors, which interact to form a regenerative micro-environment. This reduces scarring and cell apoptosis, while also promoting angiogenesis and mitosis of stem and progenitor cells within the target tissue. This mechanism is broadly referred to as 'trophic activity,' as it is supplementary and not linked with the primary differentiation of these stem cells. 141 Secondly, MSCs display immunoregulatory properties and can suppress T-cell activation through inhibition of TNF and INF , thereby increasing IL-10 levels. 142 143 These properties of MSCs have generated scientific interest in the possibility of their use in a number of clinical applications. 144 Immunoregulation has important implications in TTE, as it protects the patient and the graft from a host immune response. Research has also shown that allogeneic MSCs produce a similar inflammatory reaction to autologous MSCs, signifying that MSC immunoregulatory properties could allow the use of non-host cells in TTE. 145 146 However, a potential problem here is that the immunomodulatory effect of MSCs could theoretically suppress the host's immune system inappropriately. This concept is controversial and discussion is on-going. 147 While tumorigenic potential is certainly less than that of hESCs, several studies have shown that MSCs can form spontaneous malignant tumours after in-vivo infusion in animal models. 148 149 As a result, chromosome status of MSCs expanded in culture need to be constantly measured to assess tumorigenic potential.
MSCs therefore provide a valuable option as a cell-seed for TTE. Many successes have been demonstrated to date, though more study is required before widespread human translation can take place.
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Comparison of Cell Outcomes A comparison study of the cellular characteristics of four cell types: epitenon tenocytes, tendon sheath fibroblasts, BMSCs and ASCs has been carried out. 146 It was found that all the cell types produced viable grafts at 6 weeks. Cell histology and collagen secretion was similar between groups, with immune reaction at a level of the native tendon, demonstrating that all of these cell-types are suitable for TTE. However, in culture, lower proliferation rates were found in epitenon tenocytes, which result in slower in-vitro expansion. Combined with the decreased availability of these cells and the difficulty of extraction, tenocytes appear to be less suitable candidates for TTE than other available cell types.
Co-Culture
Co-culture of different cell types has been used to investigate if interaction between different cell types can produce outcomes greater than the sum of their parts. It has been found that co-culturing MSCs with tenocytes produces viable cells that can reciprocally exchange vesicles. 150 A 50:50 ratio of cells was found to improve tenogenic differentiation of MSCs, with a subsequent increase in expression of ECM proteins to the level of tenocytes alone. Work in ligament engineering has provided supportive results, with significantly improved Collagen-I and Tenascin-C expression in co-culture of MSCs with anterior cruciate ligament cells. 151 While there may be advantages to MSC function with co-culture, this method combines the practical failings of tenocyte extraction, with the added difficulty of multiple extraction processes, rather than a single procedure. Unless future work can produce improved results in tendon function following co-culture, it seems that this method is not practical for TTE clinical use.
As an alternative, it has been found that mono-culture of MSCs with supernatant derived from tenocytes produces collagen and scleraxis expression similar to that of coculture and tenocytes alone. 150 The isolated ECM of tenocytes may, therefore, improve tenogenic differentiation of MSCs. This may provide the benefits of co-culture, without the practical difficulties. More study is required to clarify and isolate the effect that this medium has on MSCs and what impact this produces in function.
Induced Pluripotency
Inducible pluripotent stem (iPS) cells are somatic cells that have been stimulated to de-differentiate back to their pluripotent state. iPS cells may present a future alternative in tissue engineering, as they possess the advantages of hESCs, but lack the ethical and practical concerns of their extraction. New equine iPS cell lines have been formed which, given the abundance of equine tendon repair models, could soon be transferred to TTE. 152 Recently, research has already been carried out with iPS cell-derived neural crest stem cells (NCSCs). In a rat-model of tendon injury, NCSCs significantly improved ECM secretion and mechanical strength. 153 However, current issues with reprogramming efficiency and safety concerns indicate that more work is required before human clinical trials can take place. 154 Nonetheless, the advent of recent techniques that improve the efficiency of induced pluripotency such as stimulus-triggered acquisition of pluripotency (STAP) may expedite this approaching technology. 155 
Biological Augmentation
Growth Factors
The addition of suitable biochemical factors is imperative for the augmentation of tendon healing and regeneration and therefore, tissue engineering. Growth factors are signalling molecules with a key regulatory role in numerous cellular processes including chemotaxis, proliferation, differentiation, adhesion and matrix synthesis. 156 Several growth factors have been implicated in the regulation of cellular responses during tendon healing, including insulin-like growth factor 1 (IGF-1), transforming growth factor (TGF-, vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and basic fibroblast growth factor (bFGF).
Growth factors can be delivered to the site of action in tendons either by direct application or by using gene transfer techniques. Direct application can be accomplished via local injection or in association with impregnated sutures or scaffolds. 157 Gene transfer therapy includes localised, in-vivo delivery of the gene encoding a growth factor or, alternatively, transplantation of in-vitro genetically modified cells. 158 IGF-1 has been shown to stimulate cell proliferation as well as collagen and proteoglycan synthesis at the site of tendon injury in-vitro. 159 Increased cell proliferation coupled with reduced soft tissue swelling has also been demonstrated in a study investigating the effects of intra-tendinous injection of IGF-1 in an equine model of flexor tendinitis. 160 Moreover, IGF-1 has been shown to reduce maximum functional deficit 161 and accelerate healing after tendon injury 162 via a potential anti-inflammatory mechanism. 161 Toughness and maximum load to failure were also improved in a rat model of rotator cuff repair using IGF-1 transduced scaffolds. 162 A recent study investigating the effects of mechano-growth factor MGF-C25E, an alternative splice variant of the IGF-1 gene, demonstrated that it promoted cell migration by increasing pseudopodia formation and decreasing cell stiffness. It was hence hypothesized that this may have an important role in facilitating tendon healing by enhancing the migration of tenocytes. 163 The three isoforms of TGF-have been shown to increase collagen type I and III production from tendon sheath fibroblasts, epitenon and endotenon tenocytes in-vitro. 164 TGF-1, specifically, has also been suggested to have a role in the regulation of type I collagen synthesis in human peritendinous tissue in-vivo. 165 However, TGF-1 has been implicated in the formation of scar tissue and adhesions during tendon healing, potentially by increasing fibroblast contraction. 166 TGF-1 neutralising antibodies have been demonstrated to increase flexion range of motion in a rabbit flexor tendon repair model, suggesting that modulation of TGF-1 levels has the potential to control tendon adhesion formation. 167 On the other hand, it has been suggested that TGF-3 functions as a negative regulator of scarring and adhesion formation at the site of tendon injury. Exogenous addition of TGF-3 to cutaneous wounds in adult rodents reduced scar formation. 168 Hence, it is thought that the incorporation of this factor in scaffolds may be vital in reducing adhesion formation in healing tendons. 169 PDGF-BB and FGF were shown to significantly increase canine flexor tendon fibroblast proliferation and collagen production when tested in-vitro and in-vivo. 170 171 Transfer of an exogenous PDGF-B gene to rat tenocytes has also been shown to increase collagen I gene expression in-vitro, suggesting that PDGF gene transfer may offer a novel way of promoting flexor tendon healing. 172 In addition to this, the supplementation of IGF-1 and PDGF-BB to aligned collagen-GAG scaffolds has been demonstrated to enhance tendon cell viability and metabolic activity in a dose-dependent mechanism. 173 A gelatin-coated bFGF releasing nylon thread has been tested in a rabbit tendon repair model. It was demonstrated that this bFGF-releasing system initially enhanced epitenon thickening and subsequently accelerated cellular proliferation at the connecting site, thus increasing the mechanical strength of repaired tendons. 174 Low dose bFGF-2 has been shown to elicit a biphasic response in BMSCs, consisting of an initial increase in cell proliferation and followed by enhanced mRNA expression of cytoskeletal elements and tendon ECM proteins. Low dose bFGF-2 also stimulated differentiation of BMSCs into a more elongated, fibroblastlike phenotype. 175 Silk/PLGA based biohybrid scaffolds seeded with BMSCs have also been investigated. The bFGF-releasing scaffold enhanced proliferation as well as tenogenic differentiation of BMSCs. Furthermore, the bFGF-releasing scaffolds displayed increased strength and stiffness. 176 Simultaneous application of multiple growth factors may have an important application in regenerative medicine. It was demonstrated that both IGF-1 and PDGF-BB were able to enhance tenocyte chemotaxis, proliferation and metabolic activity within a collagen-GAG scaffold, whilst maintaining tenocytic phenotype. On the other hand, bFGF and GDF-5 had little impact on tenocyte chemotaxis and proliferation, but were able to upregulate transcript levels of tenocyte-associated structural proteins and expression of tenocyte phenotypic markers. It was subsequently shown that IGF-1/GDF-5 pairing enhanced expression of COL1A2, COMP and SCXB, but also induced collagen synthesis. These results suggest that it is possible to combine growth factors to simultaneously accelerate tenocyte proliferation, whilst preserving gene expression profiles and phenotype of the tenocytes. 177 Platelet-Rich Plasma Platelet-rich plasma (PRP) is an autologous concentrated platelet product with the potential of releasing numerous growth factors, including PDGF, epidermal growth factor (EGF), TGF-, IGF-1, VEGF and bFGF. 178 179 It is a novel treatment modality, used as a biological adjunct for the treatment of tendon pathologies. However, plateletrich plasma preparations and application techniques can be variable. Platelets may be activated in-vitro, with thrombin or calcium, forming a network of fibrin which can be incorporated into a suture construct. Alternatively, PRP can be applied in an inactivated form, via a syringe or catheter, and be activated in-vivo. 180 A recent systematic review, including in-vivo and in-vitro studies investigated the effects of PRP on tendons and tenocytes. It suggested that platelet-rich plasma appears to confer multiple beneficial effects including increased cell proliferation and vascularity, accelerated tendon repair, increased fibre organization and increased tensile strength. However, it was concluded that further clinical studies of higher methodological quality are imperative in order for the exact potential of PRP in tendon healing and repair to be elucidated. 179 A recent double-blind randomized controlled trial examined the effects of leukocyte-rich PRP in patients with patellar tendinopathy, by comparing ultrasound (US)-guided PRP injection versus US-guided dry needling alone. Based on patient reported outcome surveys, it was concluded that a regime including standardised eccentric exercises together with US-guided leukocyte-rich PRP injection increases the rate of recovery from patellar tendinopathy, but the benefit of PRP injection seems to dissipate over time. 181 Despite the fact that PRP seems to confer beneficial effects when studied in-vitro or in animal models, clinical studies investigating the effect of PRP in the management of tendinopathy have so far yielded very limited and inconsistent data. Therefore, larger double blind randomised controlled trials need to be undertaken in order for definite conclusions to be drawn. 182 Gene Transfer A limitation associated with the direct application of growth factors is their transient residence time. This has led to the development of gene transfer techniques which involve transfer of the gene encoding the specific growth factor, rather than the growth factor itself, to the injured tendon, hence facilitating more prolonged exposure. 158 However, delivery of foreign genes to cells is limited by the natural protective mechanisms. Vectors for gene transfer can be either viral, or non-viral, such as liposomes. Notes: ECM, extracellular matrix; DNA, deoxyribonucleic acid; MSCs, mesenchymal stem cells; OPF, oligo (poly(ethylene glycol)fumarate); PET, polyethylene terephthalate; PGA, poly(glycolic acid); PLCL, poly(lactic-co-glycolic acid); P(LLA-CL), poly(l-lactide-co--caprolactone); RGD, Arginylglycylaspartic acid.
Viral vectors may potentially be more pathogenic, but they are also more efficient at delivering genes to eukaryotic cells, since this represents the main pathway of infection. The ideal viral vector needs to provide a highly efficient cell transduction, but also have an acceptable safety profile. 183 The primary vectors in use include adenovirus, adeno-associated virus (AAV), retrovirus, and lentivirus.
The bFGF gene has been transferred to proliferating tenocytes in-vitro, using adeno-associated viral (AAV) vectors, resulting in an increase in the expression of bFGF, collagen I and collagen III genes in the treated tenocytes. 184 A further study investigated the effects of in-vivo transfer of the PDGF-B gene to injured rat patellar ligaments using hemagglutinin virus of Japan-conjugated liposomes. The gene transfer enhanced the expression of PDGF for up to 4 weeks after transfection, leading to an initial enhancement of angiogenesis, followed by increased collagen deposition in the wound. 185 Transfer of the PDGF-B gene in an in-vitro tenocyte culture model has also been shown to significantly increase the expression of the genes coding for PDGF and type I collagen. 172 Investigation into TGF-has been carried out on Achilles tendon injuries in a rabbit model treated with TGF-1 transfected BMSCs. Higher concentrations of collagen type I, larger fibre bundles and more rapid matrix remodeling was found, suggested that TGF-1 can improve mechanical strength in a healing Achilles tendon. 186 TGF-1 transduced BMSCs have also been shown to accelerate healing and improve biomechanical properties of the injured Achilles tendon in rabbits. 187 IGF-1 gene enhanced BMSCs also have been investigated in tendon healing, using an equine collagenase model of flexor tendinitis. It was concluded that the beneficial effects of IGF-1 were minimal compared to the control, hence suggesting that further research is required to enhance IGF-1 gene delivery. 188 
Mechanical Stimulation
During tendon healing and repair, both biochemical and mechanical cues are essential. Mechanical loading of tendon results in an interstitial increase in growth factors, which may potentially stimulate collagen and other ECM protein synthesis. The frequency of stimulation, however, appears to be important (Table VIII) .
Constant mechanical stimulation has been found to have a negative impact on tendon diameter, 197 also inhibiting cell proliferation and increasing apoptosis, potentially through the increase of heat shock protein (HSP) 72 expression. 200 Native tendons are subjected to a more dynamic form of stress; which generated in bioreactors has been found to increase mechanical strength of cells to up to three times greater than non-loaded cells, producing histological results more akin to the native tendon. 199 This effect was further investigated on hESC-derived MSCs seeded on a collagen-silk scaffold. It was found that dynamic mechanical stimulation directed ESCs into a tenocyte-like morphology, expressing tendon-related markers and other mechano-sensory molecules. 44 Cyclic strain has also been shown to upregulate BMSC tendon/ligament fibroblastic genes: collagen I, collagen III and tenascin-C after 21 days in culture. 191 The effect of different forms of mechanical stimulation on cell proliferation and ECM synthesis has been investigated, using rabbit patellar tendon fibroblasts seeded on hybrid chitosan-hyaluronan scaffolds. 193 The scaffolds were subject to tensile, rotational and combined tensile-rotational stress with the aid of bioreactors. The results demonstrated that the combined group had significantly greater DNA and mRNA content of collagen I, collagen III and fibromodulin compared to static, stretch and rotational groups. Mechanical stimulation, therefore, appears to be a positive factor in tendon development and will likely be integral to future TTE strategies. Further work is required, however, to elucidate the optimal form and frequency of mechanical stimulation, which may well vary depending on the organ and animal model used.
CONCLUSION
Tendon injury remains a common clinical problem, with current treatment strategies unable to restore the tendon to its native state. Tissue engineering offers a solution to this, with many approaches producing mechanical strength superior to that seen in natural tendon healing.
Natural and synthetic scaffolds have been investigated, each providing benefits and drawbacks, but recent work has produced mechanically stable scaffolds that display suitable biofunctional properties in animal studies. An area that shows particular promise for the future is in the development of nanocomposite scaffolds, [201] [202] [203] [204] constructed with heterogeneous materials to more easily suit the needs of the regenerating tendon. In cell-seeding, aMSCs and recent developments in iPS technology hold much promise to provide a safe, reproducible method of generating cells that promote tendon healing. Growth factors also clearly have a role in this regenerative process, but more research is required to elucidate specific mechanisms of contribution. Furthermore, additional research into growth factor combination and gene therapy are likely to yield fruitful results in the future. Finally, mechanical stimulation is likely to form an integral part of graft formation for TTE, but further optimisation is required in terms of form and frequency of stimuli. With further refinement and combination of these components, tissue engineering displays a very convincing option for the restoration of the injured tendon.
